Pharmaceuticals

Krystexxa Market Forecast 2026–2035: How to Leverage Market Growth

March 5, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the krystexxa market from 2026–2035 with trusted insights from The Business Research Company

What level of growth is expected in the Krystexxa Market between 2026 and 2030?

Historical growth was fueled by the constraints of traditional gout treatments, the growing occurrence of chronic gout, the clinical efficacy demonstrated by pegloticase, an increase in co-existing health conditions, and the expansion of specialized rheumatology practices.

Projected growth during this period stems from an expanding number of patients suffering from refractory gout, an increase in referrals to specialized clinics, the broadening of infusion services, advantageous reimbursement policies for biologics, and a persistent unmet need in severe gout conditions.

Significant trends foreseen for the forecast duration involve an upsurge in biologic treatments for refractory gout, a strategic focus on therapies utilizing uric acid-lowering enzymes, the specialized management of patients with chronic gout, an expansion of rheumatology care delivered via infusion, and a growing application in severe and treatment-resistant scenarios.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20134&type=smp

Which Drivers Are Expected To Impact The Krystexxa Market During The Forecast Period?

The rising occurrence of gout disease is anticipated to drive the expansion of the Krystexxa market moving ahead. Gout is an arthritic condition resulting from the accumulation of uric acid crystals within joints, which causes inflammation, discomfort, and swelling. This growing prevalence of gout is linked to elements like unhealthy eating patterns, excess weight, advancing age, specific drugs, genetic predisposition, long-term kidney issues, inactive lifestyles, and co-occurring health problems such as hypertension and diabetes. Krystexxa (pegloticase) assists individuals with gout by decreasing blood uric acid concentrations, particularly addressing chronic gout unresponsive to standard therapies, consequently diminishing the occurrence and intensity of gout attacks and alleviating the painful indicators linked to the ailment. For example, data from June 2024, published by Rheumatology and Therapy, a US-based international peer-reviewed medical journal, indicated that the incidence of concurrent gout and chronic kidney disease in the United States was projected to rise from 7.9 million in 2023 to 8.6 million in 2027, then to 9.2 million in 2031, and eventually to 9.6 million in 2035, showing a 29% growth between 2023 and 2035. Consequently, the rising occurrence of gout disease is fueling the Krystexxa market.

Which Segments Are Driving Activity In The Krystexxa Market?

The krystexxa market covered in this report is segmented –

1) By Formulation: Injectable Formulation (Lyophilized Powder), Ready-To-Use Solutions

2) By Indication: Treatment Of Chronic Gout, Management Of Hyperuricemia In Gout Patients, Treatment Of Refractory Gout

3) By Patient Demographics: Adult Patients, Elderly Patients, Patients With Comorbid Conditions

4) By Distribution Channel: Direct Sales, Wholesalers And Distributors, Retail Pharmacies, Online Pharmacies

5) By End User: Hospitals, Specialty Clinics, Rheumatology Practices, Home Healthcare Providers

What Trends Are Projected To Support The Growth Of The Krystexxa Market?

A primary focus within the Krystexxa market involves the progression of immunomodulatory strategies, including the rheumatology research dissemination initiative, which aims to enhance the visibility of clinical evidence, facilitate well-informed therapeutic choices, and deepen stakeholder comprehension of new developments in inflammatory and autoimmune disease management. The rheumatology research dissemination initiative constitutes a structured scientific communication endeavor dedicated to presenting, sharing, and advancing novel clinical discoveries, treatment outcomes, and research findings within the rheumatology field. For instance, in June 2024, Amgen Inc., a US-based biotechnology company, showcased groundbreaking rheumatology research at the European Alliance of Associations for Rheumatology (EULAR) 2024 Congress, revealing new clinical information concerning Krystexxa (pegloticase). This study further provided extensive data on treatment response patterns, patient-reported results, and immunological characteristics when utilizing advanced therapeutic combinations. Krystexxa, a PEGylated uricase enzyme therapy, consistently exhibits distinct clinical advantages for adults suffering from uncontrolled chronic gout by employing precise immune modulation to enhance effectiveness and control the development of anti-drug antibodies. These recent findings presented by Amgen underscore Krystexxa’s significance as a premier biologic treatment option for severe gout patients who have not adequately responded to conventional therapies.

Which Leading Companies Dominate The Krystexxa Market Share?

Major companies operating in the krystexxa market are Amgen Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/krystexxa-global-market-report

How Does The Krystexxa Market Perform Across Major Global Regions?

North America was the largest region in the krystexxa market in 2025. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the krystexxa market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Krystexxa Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20134&type=smp

Browse Through More Reports Similar to the Global Krystexxa Market 2026, By The Business Research Company

Data Lake Market Report 2026

https://www.thebusinessresearchcompany.com/report/data-lake-global-market-report

Inductor Market Market Report 2026

https://www.thebusinessresearchcompany.com/report/inductor-market-global-market-report

Trade Finance Market Report 2026

https://www.thebusinessresearchcompany.com/report/trade-finance-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795